Combined with an immunoadjuvant (granulocyte macrophage-colony stimulating factor (GM-CSF)), the HER2-targeting vaccine nelipepimut-S has been shown to induce E75-specific CD8+ T-cells expansion, which is even greater in patients with HER2-low BC [42]. Here, ERBB2 is linked to breast cancer.